Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Immunity to Tumour Antigens

Author(s): G. Li, S. A. Ali, S. E.B. McArdle, S. Mian, M. Ahmad, A. Miles and R. C. Rees

Volume 11, Issue 27, 2005

Page: [3501 - 3509] Pages: 9

DOI: 10.2174/138161205774414583

Price: $65

Abstract

During the last decade, a large number of human tumour antigens have been identified. These antigens are classified as tumour-specific shared antigens, tissue-specific differentiation antigens, overexpressed antigens, tumour antigens resulting from mutations, viral antigens and fusion proteins. Antigens recognised by effectors of immune system are potential targets for antigen-specific cancer immunotherapy. However, most tumour antigens are self-proteins and are generally of low immunogenicity and the immune response elicited towards these tumour antigens is not always effective. Strategies to induce and enhance the tumour antigen-specific response are needed. This review will summarise the approaches to discovery of tumour antigens, the current status of tumour antigens, and their potential application to cancer treatment.

Keywords: tumour antigen, immunotherapy, antigen discovery, tolerance


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy